Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

41P - HLA genotypes modify the age-related penetrance of BRCA1 pathogenic variants in breast cancer patients

Date

04 Oct 2023

Session

Cocktail & Poster Display session

Presenters

Ekaterina Kuligina

Citation

Annals of Oncology (2023) 8 (suppl_1_S5): 1-55. 10.1016/esmoop/esmoop101646

Authors

E.S. Kuligina1, A.A. Romanko1, A.S. Martianov1, J.A. Gorgul1, A. Kashyap2, C. Cybulski2, J. Lubinski2, D.S. Trofimov3, T. Jankevic3, E. Imyanitov1

Author affiliations

  • 1 Department Of Tumor Biology, N.N. Petrov National Medical Research Center of Oncology, 197758 - Saint-Petersburg/RU
  • 2 International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, 70-204 - Szczecin/PL
  • 3 DNA-Technology, 117587 - Moscow/RU

Resources

This content is available to ESMO members and event participants.

Abstract 41P

Background

Most female carriers of germline BRCA1 mutation develop breast and/or ovarian cancer. However, the penetrance of BRCA1 pathogenic variants does not reach 100%, and the age at onset for BRCA1-associated breast cancer (BC) varies widely. This study aimed to evaluate whether the age-related likelihood of developing BC in BRCA1 mutation carriers is influenced by inherited variations in the host immune system.

Methods

Next-generation sequencing was utilized for genotyping of HLA class I and II genes (HLA-A, HLA-B, HLA-C, HLA-DPB1, HLA-DQB1, and HLA-DRB1/3/4/5) in patients with BRCA1-associated BC with early (<39 years, n = 215) and late (>57 years, n=108) age at onset. Age thresholds corresponding to the youngest and oldest quartiles of women were determined by analyzing the age distribution in 771 consecutive female BC patients carrying BRCA1 pathogenic variants.

Results

HLA-DQB1*06:03P prevalence was higher in the late-onset group due to the excess of allele carriers [25/108 (23.1%) vs. 22/215 (10.2%); adjusted OR 2.96 (95% CI 1.58 - 5.56), p < 0.001] and homozygous genotypes [3/108 (2.8%) vs. 0/215 (0%); OR 14.3 (95% CI 0.73 - 279.27), p = 0.08]. For all HLA-I loci, there was a trend toward an increase in the number of homozygous genotypes in the early-onset group. For the HLA-A locus this prevalence was significant [14.4% vs. 6.5%, p = 0.037; OR 2.4 (95% CI 1.03 - 5.72), p = 0.042]. The frequencies of HLA-DPB1, HLA-DQB1, and HLA-DRB3/4/5 homozygous genotypes did not differ between young-onset and late-onset BC patients. The maximum degree of homozygosity detected in this study was 6 out of 7 HLA class I/II loci; all six female carriers of these genotypes were diagnosed with BC before the age of 39 years [OR = 6.97 (95% CI 0.39 - 125.01), p = 0.187].

Conclusions

HLA-DQB1*06:03P is significantly overrepresented in late-onset versus young-onset BRCA1 heterozygous BC patients suggesting that this allele has a protective role. A reduced diversity of HLA class I alleles may contribute to the early manifestation of BC in BRCA1 mutation carriers.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

Russian Science Foundation grant #22-15-00278.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.